We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+4.14%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$3.14B
AUM Growth
+$264M
Cap. Flow
+$499M
Cap. Flow %
15.9%
Top 10 Hldgs %
65.37%
Holding
91
New
20
Increased
10
Reduced
3
Closed
15
Avg Time Held Equity + Options
3.4 quarters
Top 10 Avg Time Held Equity + Options
4.6 quarters
Top 20 Avg Time Held Equity + Options
4.9 quarters
Avg Time Held Equity only
3.5 quarters
Top 10 Avg Time Held Equity only
4.6 quarters
Top 20 Avg Time Held Equity only
4.9 quarters

Top Buys

Rank Stock Value
1
APLS icon
Apellis Pharmaceuticals
APLS
+$159M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$94.1M
3
AVIR icon
Atea Pharmaceuticals
AVIR
+$83.8M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$61.6M
5
TSVT icon
2seventy bio
TSVT
+$59.8M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$82.1M
2
STTK icon
Shattuck Labs
STTK
+$75.6M
3
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$25.2M
4
NRIX icon
Nurix Therapeutics
NRIX
+$24.8M
5
BLUE icon
bluebird bio
BLUE
+$15.3M

Sector Composition

Rank Sector Weight
1 Healthcare 98.9%
2 Financials 0.62%
3 Miscellaneous 0.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
PRTA icon
1
Prothena Corp
PRTA
$429M
$557M 17.76%
11,284,280
– –
2018 Q4
12 quarters
ANAB icon
2
AnaptysBio
ANAB
$1.36B
$261M 8.33%
7,521,024
– –
2019 Q4
8 quarters
RCUS icon
3
Arcus Biosciences
RCUS
$2.87B
$224M 7.12%
5,523,358
+400,999
+8% +$15.6M
2018 Q1
15 quarters
XNCR icon
4
Xencor
XNCR
$1.75B
$197M 6.27%
4,906,106
– –
2018 Q4
12 quarters
APLS icon
5
DELISTED
Apellis Pharmaceuticals
APLS
$191M 6.08%
+4,033,882
New +$159M
2021 Q4
0 quarters
MORF icon
6
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$187M 5.97%
3,951,566
– –
2019 Q2
10 quarters
LKFT icon
7
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.9B
$123M 3.91%
2,224,403
+665,654
+43% +$34.7M
2021 Q3
1 quarter
NUVB icon
8
Nuvation Bio
NUVB
$1.66B
$118M 3.76%
13,896,543
+185,026
+1% +$1.7M
2021 Q1
3 quarters
ALEC icon
9
Alector
ALEC
$209M
$103M 3.29%
4,994,970
– –
2021 Q1
3 quarters
PTGX icon
10
Protagonist Therapeutics
PTGX
$8.96B
$90.3M 2.88%
2,639,706
+1,195,906
+83% +$37.8M
2021 Q3
1 quarter
CRSP icon
11
CRISPR Therapeutics
CRSP
$4.84B
$81.7M 2.6%
+1,077,483
New +$94.1M
2021 Q4
0 quarters
GRTS icon
12
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$77.3M 2.46%
6,012,232
+451,484
+8% +$5M
2020 Q4
4 quarters
ACAD icon
13
Acadia Pharmaceuticals
ACAD
$3.21B
$71.4M 2.28%
+3,060,593
New +$61.6M
2021 Q4
0 quarters
RNAM
14
DELISTED
Avidity Biosciences
RNAM
$65.6M 2.09%
2,759,505
– –
2020 Q2
6 quarters
ITOS icon
15
DELISTED
iTeos Therapeutics
ITOS
$60.7M 1.93%
1,303,157
– –
2020 Q3
5 quarters
RLAY icon
16
Relay Therapeutics
RLAY
$3.8B
$54.6M 1.74%
1,779,084
+393,808
+28% +$12.4M
2020 Q3
5 quarters
KURA icon
17
Kura Oncology
KURA
$874M
$52.1M 1.66%
3,724,437
– –
2015 Q4
24 quarters
ORIC icon
18
Oric Pharmaceuticals
ORIC
$1.17B
$51M 1.63%
3,468,944
– –
2020 Q2
6 quarters
TSVT icon
19
DELISTED
2seventy bio
TSVT
$49.1M 1.57%
+1,917,063
New +$59.8M
2021 Q4
0 quarters
AVIR icon
20
Atea Pharmaceuticals
AVIR
$399M
$48.1M 1.53%
+5,376,134
New +$83.8M
2021 Q4
0 quarters
DSGN icon
21
Design Therapeutics
DSGN
$612M
$46.1M 1.47%
2,152,997
+289,899
+16% +$4.98M
2021 Q1
3 quarters
SAGE icon
22
DELISTED
Sage Therapeutics
SAGE
$40M 1.28%
+940,636
New +$39.4M
2021 Q4
0 quarters
JANX icon
23
Janux Therapeutics
JANX
$1.05B
$27.9M 0.89%
1,411,975
– –
2021 Q2
2 quarters
PRDS
24
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$26.1M 0.83%
1,597,139
+1,226,125
+330% +$14.3M
2021 Q1
3 quarters
VTYX icon
25
DELISTED
Ventyx Biosciences
VTYX
$25.8M 0.82%
+1,300,000
New +$24.6M
2021 Q4
0 quarters
1
2 3 4

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q4 2021 Portfolio in Review

As of Q4 2021, EcoR1 Capital held 91 positions worth $3.14B, up 9.2% from $2.87B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

EcoR1 Capital deployed $499M of net new capital in Q4 2021, opening 20 new positions and adding to 10 existing holdings. Its largest new stake was Apellis Pharmaceuticals: 4,033,882 shares worth $191M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Financials and Miscellaneous.

On the sell side, the largest reduction was Nurix Therapeutics, an estimated $24.8M trimmed.

  • EcoR1 Capital's largest Q4 2021 buy was Apellis Pharmaceuticals: 4,033,882 shares worth $191M.
  • EcoR1 Capital added most to Protagonist Therapeutics in Q4 2021, an estimated $37.8M increase.
  • EcoR1 Capital's biggest Q4 2021 reduction was Nurix Therapeutics, cutting an estimated $24.8M.
  • EcoR1 Capital fully exited Mirati Therapeutics, Inc. Common Stock in Q4 2021, selling an estimated $82.1M.
  • EcoR1 Capital's ten largest holdings make up 65% of its $3.14B portfolio in Q4 2021.
  • EcoR1 Capital opened 20 new positions and closed 15 in Q4 2021.
  • EcoR1 Capital's portfolio value rose 9.2% quarter-over-quarter to $3.14B.

Based on EcoR1 Capital's 13F filing for Q4 2021, filed 14 Feb 2022.